var data={"title":"Quinupristin and dalfopristin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Quinupristin and dalfopristin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6888?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">see &quot;Quinupristin and dalfopristin: Drug information&quot;</a> and <a href=\"topic.htm?path=quinupristin-and-dalfopristin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Quinupristin and dalfopristin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216636\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Synercid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216637\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Synercid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049658\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Streptogramin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049651\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">see &quot;Quinupristin and dalfopristin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage is expressed in terms of combined &ldquo;mg&rdquo; of quinupristin plus dalfopristin: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: Limited data in infants and children &lt;12 years: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i>, 2012): IV: Severe infection: 15-22.5 mg/kg/day in divided doses every 8-12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Enterococcus faecium, vancomycin resistant (VREF):</b> Limited data available: IV:  7.5 mg/kg/dose every 8 hours; dosing based on an Emergency-Use Program [n=127, mean age: 7.3 years (range: 1.2 months to 17 years)] (Loeffler, 2002) and  a case series (n=8, range: 17 months to 18 years) (Gray, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MRSA, vancomycin failure salvage therapy:</b> IV: 7.5 mg/kg/dose every 8 hours (Liu, 2011; Loeffler, 2002) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infection; complicated, treatment:</b> IV:  7.5 mg/kg/dose every 12 hours for at least 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>VP-shunt infection, ventriculitis:</b> Limited data available: Intraventricular/intrathecal <b>(use a preservative-free preparation)</b>: Usual dose: 1-2 mg/<b>day</b>; reported range: 1-5 mg; administered with concurrent IV quinupristin/dalfopristin therapy (Nachman, 1995; Tunkel, 2004; Tush, 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacteremia, MRSA (persistent, vancomycin failure):</b> IV: 7.5 mg/kg every 8 hours (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infection; complicated, treatment:</b> IV: 7.5 mg/kg/dose every 12 hours for at least 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment is required for use in patients with renal impairment or patients undergoing peritoneal dialysis. Not removed by peritoneal dialysis or hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer labeling; not studied; pharmacokinetic data suggest adjustment may be necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216618\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synercid&reg;: 500 mg: Quinupristin 150 mg and dalfopristin 350 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216604\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049661\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Administer infusion over 60 minutes (toxicity may be increased with shorter infusion); prior to and following administration, the infusion line should be flushed with D<sub>5</sub>W to minimize venous irritation; <b>DO NOT FLUSH</b> with saline or heparin solutions due to incompatibility. If severe venous irritation occurs following peripheral administration, quinupristin/dalfopristin may be further diluted, infusion site changed, or infused by a peripherally inserted central catheter (PICC) or a central venous catheter. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216632\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Stability of the solution diluted in D5W prior to the infusion is 5 hours at room temperature or 54 hours at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Extended storage information may be available; contact product manufacturer to obtain current recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049660\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of complicated skin and skin structure infections caused by <i>Staphylococcus aureus</i> (methicillin-susceptible) or <i>Streptococcus pyogenes</i> (FDA approved in ages &ge;12 years and adults); has also been used for salvage therapy for invasive MRSA infections in cases of vancomycin treatment failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216663\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, increased gamma-glutamyl transferase, increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Infusion site reaction, local inflammation (at infusion site), local pain, localized edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, apnea, brain disease, cardiac arrhythmia, dysautonomia, dyspnea, gout, hematuria, hemolytic anemia, hepatitis, hyperkalemia, hypersensitivity reaction, hypotension, maculopapular rash, mesenteric artery occlusion, myasthenia, neuropathy, pancreatitis, pancytopenia, paraplegia, paresthesia, pericarditis, pleural effusion, pseudomembranous colitis, respiratory distress, seizure, shock, stomatitis, syncope, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216623\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to quinupristin, dalfopristin, other streptogramins (eg, pristinamycin, virginiamycin), or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216608\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arthralgias/myalgias: May cause arthralgias and/or myalgias, sometimes severe; reversible with treatment discontinuation. Reduction of dosing frequency has led to improvement in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperbilirubinemia: May cause hyperbilirubinemia (&gt;5 times ULN; primarily conjugated bilirubin) possibly through competition for excretory pathways.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phlebitis: May cause pain and phlebitis when infused through a peripheral line (not relieved by hydrocortisone or diphenhydramine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216654\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216613\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12758&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Quinupristin may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216625\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049657\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, liver function test; monitor infusion site closely; number and type of stools/day for diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216607\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Quinupristin/dalfopristin inhibits bacterial protein synthesis by binding to different sites on the 50S bacterial ribosomal subunit thereby inhibiting protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216622\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Quinupristin: 0.45 L/kg; Dalfopristin: 0.24 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Quinupristin is conjugated with glutathione and cysteine to active metabolites; dalfopristin is hydrolyzed to an active metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Quinupristin: 0.85 hour; Dalfopristin: 0.7 hour (mean elimination half-lives, including metabolites: 3 and 1 hours, respectively) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (75% to 77% as unchanged drug and metabolites); urine (15% to 19%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323773\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Synercid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150-350 mg (1): $486.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038795\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pyostacine (BE, LU);</li>\n      <li>Synercid (FR, GR, HN, IT, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Garey KW, Tesoro E, Muggia V, et al, &quot;Cerebrospinal Fluid Concentrations of Quinupristin-Dalfopristin in a Patient With Vancomycin-Resistant <i>Enterococcus faecium</i> Ventriculitis,&quot; <i>Pharmacotherapy</i>, 2001, 21(6):748-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-pediatric-drug-information/abstract-text/11401187/pubmed\" target=\"_blank\" id=\"11401187\">11401187</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gransden WR, King A, Marossy D, et al, &quot;Quinupristin/Dalfopristin in Neonatal <i>Enterococcus faecium</i> Meningitis,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 1998, 78(3):F235-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-pediatric-drug-information/abstract-text/9713046/pubmed\" target=\"_blank\" id=\"9713046\">9713046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gray JW, Darbyshire PJ, Beath SV, et al, &quot;Experience With Quinupristin/Dalfopristin in Treating Infections With Vancomycin-Resistant <i>Enterococcus faecium</i> in Children,&quot; <i>Pediatr Infect Dis J</i>, 2000, 19(3):234-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-pediatric-drug-information/abstract-text/10749466/pubmed\" target=\"_blank\" id=\"10749466\">10749466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupte G, Jyothi S, Graham S, et al, &quot;Synercid Use in Children Is Associated With Arthralgia and Myalgia,&quot; <i>Archives of Disease in Childhood</i>, 2006, 91(Supp 1):67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loeffler AM, Drew RH, Perfect JR, et al, &quot;Safety and Efficacy of Quinupristin/Dalfopristin for Treatment of Invasive Gram-Positive Infections in Pediatric Patients,&quot; <i>Pediatr Infect Dis J</i>, 2002, 21(10):950-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-pediatric-drug-information/abstract-text/12394819/pubmed\" target=\"_blank\" id=\"12394819\">12394819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nachman SA, Verma R, and Egnor M, &quot;Vancomycin-Resistant <i>Enterococcus faecium</i> Shunt Infection in an Infant: An Antibiotic Cure,&quot; <i>Microb Drug Resist</i>, 1995, 1(1):95-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quinupristin-and-dalfopristin-pediatric-drug-information/abstract-text/9156389/pubmed\" target=\"_blank\" id=\"9156389\">9156389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>, 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12758 Version 79.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216636\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216637\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049658\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049651\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216618\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F216604\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049661\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F216632\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049660\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216663\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216623\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216608\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F216654\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216613\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216625\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049657\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216607\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F216622\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323773\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038795\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12758|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">Quinupristin and dalfopristin: Drug information</a></li><li><a href=\"topic.htm?path=quinupristin-and-dalfopristin-patient-drug-information\" class=\"drug drug_patient\">Quinupristin and dalfopristin: Patient drug information</a></li></ul></div></div>","javascript":null}